XML 35 R24.htm IDEA: XBRL DOCUMENT v3.26.3
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 14 - SEGMENT INFORMATION

 

The Company has one operating and reporting segment that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the chief executive officer, evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources, and assess performance.

 

The CODM examines, within each operational function, the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

 

   2026   2025   2026   2025 
   Three months ended
September 30,
   Nine months ended
September 30,
 
   2026   2025   2026   2025 
Revenues   2,242    2,523    7,411    5,830 
                     
Cost of Revenues:                    
Material and Labor   1,725    1,391    5,047    3,554 
Other cost of revenues   277    268    1,126    807 
Inventory write-off   -    -    1,085    - 
Total Cost of Revenues   2,002    1,659    7,258    4,361 
                     
Research and development (R&D)                    
Payroll and Benefits   1,178    1,089    4,059    3,063 
Share based compensation   (204)   576    406    1,889 
Clinical trials   1,224    1,105    3,663    3,401 
Other R&D   1,075    865    4,203    3,175 
Total Research and development   3,273    3,635    12,331    11,528 
                     
Selling and marketing (S&M)                    
Payroll and Benefits   2,618    2,975    10,411    7,732 
Share based compensation   (649)   567    475    1,379 
Other S&M   425    850    1,909    2,203 
Total Selling and marketing   2,394    4,392    12,795    11,314 
                     
General and administrative (G&A)                    
Payroll and Benefits   1,185    1,707    4,148    5,015 
Share based compensation   801    2,351    3,267    6,051 
Other G&A   1,466    1,830    4,914    5,091 
Total General and administrative   3,452    5,888    12,329    16,157 
                     
Total Restructuring   1,074    -    1,074    - 
                     
Financial Income (expenses), net;   191    343    601    505 
Segment net loss   (9,762)   (12,708)   (37,775)   (37,025)